Rafael Holdings (RFL) – StreetInsider.com Reports
-
Rafael Holdings (RFL) Reports Q4 EPS of $0.06
-
Rafael Holdings (RFL) Announces Resignation of Rachel Jonas from Board
-
Rafael Holdings (RFL) Announces up to $5 Million Share Repurchase Program
-
Rafael Holdings (RFL) to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities
-
Rafael Holdings (RFL) Receives Notice of Allowance for US Patent Related to Pancreatic Cancer
-
Rafael Holdings (RFL) Sells Newark Building for $49.4M
-
Rafael Holdings (RFL) Halted, News Pending
-
EMA Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613 for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer (RFL)
-
Rafael Holdings (RFL) Announces 2.83M Share Offering by Selling Stockholders
-
Rafael Holdings (RFL) Announces William Conkling Will Assume CEO Role on February 1, 2022
-
EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ CPI-613 (Devimistat) for Treatment of Patients with Relapsed or Refractory Burkitt's Lymphoma (RFL)
-
Rafael (RFL) AVENGER 500 Phase 3 clinical trial evaluating CPI-613 in combination with modified FOLFIRINOX (mFFX) as a first-line therapy in patients misses primary endpoint
-
Rafael Holdings (RFL) Announces CPI-613 Did Not Meet Primary Endpoints in Phase 3 Trial
-
Rafael Holdings (RFL) Appoints Mimi Huizinga, MD, MPH as Chief Development and Medical Officer
-
Rafael Holdings (RFL) Appoints Patrick Fabbio as CFO
-
Rafael Holdings (RFL) Announces Successful Completion of Phase 1b Clinical Trial and Initiates Phase 2 for CPI-613 in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer
-
Rafael Holdings (RFL) Announces $104.2 Million Private Placement of Common Stock
-
Rafael Holdings (RFL) Announces Positive Preplanned Interim Futility Analysis of Pivotal Phase 3 Trial of CPI-613 for Relapsed or Refractory Acute Myeloid Leukemia
-
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613 (Devimistat) for Treatment of Biliary Cancer (RFL)
-
Rafael Holdings (RFL) Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company
-
Rafael Holdings (RFL) Appoints Ameet Mallik, Shannon Thyme Klinger and Mark McCamish to its Board
-
Rafael Holdings (RFL) Receives FDA Fast Track Designation for CPI-613 for Treatment of AML
-
Rafael Holdings (RFL) Reports FDA Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma
-
Rafael Holdings (RFL) Reports 100th Patient Enrollment in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for R/R AML
-
Rafael Holdings (RFL) Begins New Phase 1 Study to Evaluate Lead Compound CPI-613 (devimistat) for Patients with Pancreatic Cancer in Japan
-
Rafael Holdings (RFL) Completes Target Enrollment of 500 Patients in Pivotal Ph. 3 Trial (AVENGER 500) of CPI-613 (devimistat) for Patients with Metastatic Pancreatic Cancer
-
Rafael Holdings (RFL) Reports Midpoint Enrollment in First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (Devimistat)
-
Rafael Holdings (RFL) Announces Collaboration to Evaluate Efficacy of CPI-613 (Devimistat) in Combination with Azacitidine & Venetoclax on AML Models
-
Rafael Holdings (RFL) Reports MD Anderson Cancer Center Begins Patient Enrollment in Phase 2 Clinical Trial of CPI-613 (devimistat)
-
Rafael Holdings (RFL) Reports Enrollment More than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat)
-
Rafael Holdings (RFL) Commences Ph. 1b/2 Clinical Trial of CPI-613 (devimistat) in Combination with Gemcitabine & Cisplatin in Patients with Biliary Tract Cancer
-
Rafael Holdings (RFL) Reaches Halfway Enrollment Point in Pivotal Ph. 3 Trial (AVENGER 500) of CPI-613 (devimistat)
-
Rafael Holdings (RFL) Reports Expansion in South Korea of Pivotal Phase 3 Trial of CPI-613 (devimistat) in Patients with Metastatic Pancreatic Cancer
-
Rafael Holdings (RFL) to Collaborate with NIH to Test CPI-613 (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma
-
Rafael Holdings (RFL) Achieves 100 Patient Enrollment Milestone in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) for Patients
-
Rafael Holdings (RFL) Reports Expansion into South Korea of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat)
-
Rafael Holdings (RFL) Reports Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX
-
Rafael Holdings (RFL) Expands Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) into Austria, South Korea and Spain
-
Rafael Holdings (RFL) Reports Expansion into Israel of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX
-
Rafael Holdings (RFL) Reports Out-Licensing Agreement with Ono Pharma for Development & Commercialization of CPI-613 (devimistat) in ASEAN Nations
-
Rafael Holdings (RFL) Reports Q2 Loss of $0.08
-
Rafael Holdings (RFL) Buys Majority Stake in Rafael Pharma
-
Rafael Holdings (RFL) Granted Orphan Drug Designation from EMA for Devimistat (CPI-613) for Treatment of Metastatic Pancreatic Cancer
-
Rafael Holdings (RFL) Commences Phase II Trial of CPI-613
-
Rafael Holdings (RFL) Commences Patient Enrollment for Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
-
Rafael Holdings (RFL) Reports Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat)
-
Rafael Holdings (RFL) Reports Q4 Loss of $0.05/Share
-
UPDATE: Rafael Holdings (RFL) Reports Q3 Loss of $0.04/Share
-
IDT Corp. (IDT) Completes Spin-Off of Rafael Holdings (RFL)
-
KBW Notes Short Interest Falls In Their Banking ETFs (KBE, KRE), But Surges In The Insurance ETF (KIE)
Back to RFL Stock Lookup
